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Abstract
Background: Chronic fatigue syndrome (CFS), multiple chemical sensitivity (MCS), and
fibromyalgia (FM) commonly co-occur. Some propose that CFS, MCS, and FM are manifestations
of the same illness based on high rates of co-occurrence and overlapping diagnostic criteria. This
study seeks to differentiate these diagnoses by comparing individuals with one or more illness on
functioning, psychiatric comorbidity, coping style, and in vivo physical measures.
Methods: Participants included 114 men and women who met criteria for CFS. FM was diagnosed
during a physical examination, and MCS was assessed using a questionnaire. Participants were
divided into four groups: CFS alone, CFS-MCS, CFS-FM, and CFS-MCS-FM. Self-report measures,
a psychiatric interview, and in vivo physical measures were given.
Results: 43.9% met criteria for CFS alone, 23.7% met criteria for CFS-MCS, 15.8% met criteria for
CFS-FM, and 16.7% met criteria for CFS-MCS-FM. The CFS-MCS-FM group was more disabled than
the CFS alone group on measures of physical functioning, general health, and bodily pain. In vivo
measures did not differ, but the CFS-MCS-FM group rated exertion higher than the CFS alone
group.
Conclusion: Individuals with CFS alone were the highest functioning group across several
domains, such as disability, depression, and severity of symptoms. Participants with three diagnoses
experienced the greatest amount of disability. While substantial co-occurrence of these illnesses
was found, this study provides evidence that having more than one illness exacerbates one's
disability beyond CFS alone.
Background
Chronic Fatigue Syndrome (CFS) is a debilitating illness
affecting approximately .42% of adults in the US [1]. A
diagnosis of CFS based on the current US case definition
[2] requires at least six months of persistent fatigue along
with at least four of eight specified symptoms (e.g.,
impaired memory and concentration, unrefreshing sleep,
post-exertional malaise). Relatively few patients with CFS
completely recover from the illness [3], with a recovery
rate of 0–6% and increased disability in 10–20% of
patients over time [4].
Many of the symptoms associated with CFS are also char-
acteristic of Fibromyalgia (FM) and Multiple Chemical
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ment characterized by chronic generalized muscle pain,
fatigue, and disrupted sleep. FM is present in about 3.4%
of American women and .5% of men [5]. It has been
found to occur following an acute medical illness, a trau-
matic injury, or surgery [6]. Proposed criteria for the diag-
nosis of FM require widespread muscular pain in
conjunction with tenderness at a minimum number of
tender points [7]. CFS and FM often co-occur [8-10]. It has
been estimated that 20–70% of FM patients meet the cri-
teria for CFS, and about 35–75% of patients with CFS also
have FM [11-13]. Patients diagnosed with both CFS and
FM have been found to be more disabled than those with
either condition alone [14], suggesting that co-occurring
CFS and FM has an additive effect on disability.
MCS is a commonly diagnosed illness, and is estimated to
occur in 6% of adults in California [15]. MCS is defined as
a chronic condition with reproducible symptoms involv-
ing multiple organ systems; with symptoms that are pro-
duced by low levels of exposure to multiple, chemically-
unrelated substances and improve or resolve when the
chemical agents are removed [16]. Common triggers
include pesticides and perfumes [15], causing skin irrita-
tion, fatigue, fevers, and neurocognitive dysfunction.
Treatment typically involves avoidance of exposure to
offending chemicals using such tactics as eliminating car-
peting, pesticides and cleaning agents from the home and
avoiding other substances experienced as toxic [17].
Chemical avoidance was found to be an effective treat-
ment in 93% of patients [18-20]. MCS is a commonly co-
occurring illness with both CFS and FM. In a sample of 33
Gulf War veterans with CFS, 42% had concurrent MCS
and 6% had concurrent FM [21]. Estimated rates of CFS
comorbidity in persons with MCS range from 30% to 88%
[11,22].
Based on the substantial co-occurrence of CFS, MCS, and
FM, it is important to examine the functional status of
individuals who experience two or more of these diag-
noses. In a tertiary care sample, Ciccone and Natelson
[23] found that women with all three diagnoses experi-
enced poorer physical functioning, more pain, and more
fatigue than those with CFS only. The study by Ciccone
and Natelson is the only one to compare all three ill-
nesses, but males were excluded from their sample. Addi-
tionally, that study did not examine stress, coping, quality
of life or measures that did not rely on self-report data.
The present study explored whether individuals with three
illnesses are more disabled than those with two or one,
and assessed different coping styles in response to their
disability. Additionally, the use of in vivo physical meas-
ures was used to supplement information from self-report
measures in order to employ multiple methods in gaining
a more comprehensive understanding of this illness.
Methods
Participant recruitment
Participants were recruited from a variety of sources,
including physician referrals. Information about the non-
pharmacologic treatment trial study was disseminated to
medical colleagues through mailings, phone communica-
tion, and invited grand rounds. In addition, study
announcements for new participants were placed in local
newspapers and recruitment offers were made at local CFS
support group meetings. These efforts were continued
until the target enrollment numbers were achieved. One
hundred and fourteen individuals were recruited. All pro-
cedures were approved by the DePaul University Institu-
tional Review Board. Informed consent was given by all
participants.
Of the 114 individuals, 46% were referred by physicians,
34% were recruited by media (newspapers, TV, radio,
etc.), and 20% stemmed from other sources (e.g., heard
about the study from a friend, family member, person in
the study, etc.). There were no significant demographic
differences for patients recruited from these varying
sources. Twenty-four additional individuals who were
screened were excluded for various reasons (i.e., lifelong
fatigue, less than 4 Fukuda symptoms, Body Mass Index >
45, melancholic depression or bipolar depression, alco-
hol or substance abuse disorder, autoimmune thyroiditis,
cancer, lupus, rheumatoid arthritis). Approaches to
reduce attrition included use of letters and telephone
reminders of all appointments, flexibility regarding work-
ing around vacations and medical and other crises, reim-
bursement for transportation costs, and participant
honoraria.
Initial screening
All participants were required to be at least 18 years of age,
not pregnant, able to read and speak English, and consid-
ered to be physically capable of attending the scheduled
sessions. Patients who were bedridden or used wheel-
chairs were excluded due to the practical difficulties of
making appointments. Referrals to local physicians who
treat CFS and to support groups were offered to these indi-
viduals. After a consent form was filled out, prospective
participants were initially screened by the third author,
using a structured questionnaire.
The CFS questionnaire
This screening scale was initially validated by Jason,
Ropacki, et al. [24]. This scale is used to collect demo-
graphics, health status, medication usage, and symptom
data. The CFS Questionnaire was revised, and adminis-
tered it to three groups: those with CFS, Major Depressive
Disorder, and healthy controls [25]. The revised instru-
ment, which was used in the present study, evidencesPage 2 of 9
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specificity.
For each symptom, participants were asked to indicate if
the symptom had been present for 6 months or longer, if
the symptom began before the onset of their fatigue or
health problems, and how often (never, seldom, often/
usually, or always) the symptom is experienced. Partici-
pants were also asked to rate the severity of each symptom
they endorsed on a scale of 0 to 100, where 0 = no prob-
lem and 100 = the worst problem possible. This is a
numerical rating scale (NRS), which has been shown to be
a consistently valid measure of symptom intensity, partic-
ularly for pain intensity [26]. The Fukuda et al. [2] case
definition symptoms (i.e., impaired memory or concen-
tration, sore throat, tender lymph nodes, muscle pain,
multiple-joint pain, new headaches, unrefreshing sleep,
and post-exertion malaise) were assessed.
A series of questions assessing MCS were included in the
CFS Questionnaire. Questions that qualified a diagnosis
of MCS included new awareness of odors, frequency of
fever (not at all through daily), how sick one would be fill-
ing his or her own gas tank (not at all through a lot), and
how sick one would be if he or she had to spend four
hours in an enclosed shopping mall (not at all through a
lot). These questions were derived from Donnay's [27]
screening survey for CFS, MCS, and FM. This survey has
evidenced diagnostic specificity of 96.7% and specificity
of 98.3% (A. Donnay, personal communication, Decem-
ber 1, 2000).
Structured clinical interview for DSM-IV
A semi-structured psychiatric interview was administered.
The Structured Clinical Interview for DSM-IV (SCID) [28].
Axis I was used to establish psychiatric diagnoses. The pro-
fessionally administered SCID allows for clinical judg-
ment in the assignment of symptoms to psychiatric or
medical categories, a crucial distinction in the assessment
of symptoms that overlap between CFS and psychiatric
disorders, e.g., fatigue, concentration difficulty, and sleep
disturbance [3]. A psychodiagnostic study [29] validated
the use of the SCID in a sample of CFS patients. Because
CFS is a diagnosis of exclusion, prospective participants
were screened for identifiable psychiatric and medical
conditions that may explain CFS-like symptoms. These
measures were completed at DePaul University and took
approximately two hours. After the initial interview was
completed, the patients' information was reviewed to
ensure that they met all eligibility requirements. If an indi-
vidual was eligible for the study, a medical appointment
was set up. Conversely, if an individual was not eligible,
alternative treatment options were discussed.
Medical assessment of CFS
The physician screening evaluation included an in-depth
medical and neurological history, as well as general and
neurological physical examinations. A modified version
of the CFS questionnaire was used to rule out other disor-
ders [30]. Relevant medical information was gathered to
exclude possible other medical causes of chronic fatigue,
including exposure histories to tuberculosis, AIDS, and
non-AIDS sexually transmitted diseases. Information on
prescribed and illicit drug use was also assessed and
recorded. The histories of all symptoms related to CFS
were gathered. Laboratory tests in the battery were the
minimum necessary to rule out other illnesses [2].
FM was diagnosed by the project physician during the
medical assessment. The 1990 criteria from The American
College of Rheumatology [7] were used. Participants
received a diagnosis of FM if they had mild to severe ten-
derness in at least 11 out of 18 established tender point
sites throughout the body.
Medical Outcomes Study-Short Form-36
(MOS-SF-36). The MOS-SF-36, a 36 item broadly-based
self-report measure of functional status related to health,
identifies eight health concepts as perceived by the indi-
vidual. The concepts include Physical Functioning, Role
Functioning-Physical, Role Functioning-Emotional, Bod-
ily Pain, General Health, Vitality, Mental Health, and
Health Transition [31]. A higher score indicates better
health or functioning. Test construction studies for the SF-
36 [32,33] have shown adequate internal consistency, dis-
criminate validity among subscales, and substantial differ-
ences between patient and non-patient populations in the
pattern of scores. The SF-36 has also indicated sufficient
psychometric properties as a measure of functional status
in a CFS population [34].
Fatigue Severity Scale (FSS)
Krupp, LaRocca, Muir-Nash, and Steinberg's [35] Fatigue
Severity Scale was used to measure fatigue. This scale
includes 9 items rated on 7-point scales and is sensitive to
different gradations of fatigue severity. Most items in the
Krupp fatigue scale are related to behavioral consequences
of fatigue. Previous findings have demonstrated the utility
of the Fatigue Severity Scale to discriminate between indi-
viduals with CFS, MS, and primary depression [36]. In
addition, the Fatigue Severity Scale was normed on a sam-
ple of individuals with MS, SLE, and healthy controls. A
study by Taylor, Jason and Torres [37] compared the
Fatigue Scale [38] with the Fatigue Severity Scale [35] with
a sample of healthy controls and a CFS-like group. Within
a CFS-like group, the Fatigue Severity Scale was more
closely associated with severity ratings for the eight
Fukuda et al. [2] CFS symptoms as well as with functional
outcomes related to fatigue.Page 3 of 9
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Because depression is the most commonly diagnosed psy-
chiatric disorder in CFS [39], a quantitative measure of
depression severity was used. Depressive symptomatology
was measured with the BDI-II [40], a 21-item self-report
instrument with well-established psychometric proper-
ties. This version of the BDI is more consonant with DSM-
IV criteria for major depressive disorder. The BDI-II is the
only depression rating scale to be empirically tested and
interpreted for both depressed and non-depressed
patients with CFS [41]. Also the Beck Depression Inven-
tory has shown sensitivity to treatment changes in two
cognitive behavioral treatment studies of CFS [42].
Brief COPE
This inventory assesses how individuals cope with the
stress in their lives [43]. It is derived from the Coping Ori-
entation to Problems Experienced Scale [44], which con-
sists of conceptually distinct problem-focused coping and
conceptually distinct emotion-focused coping scales. This
instrument has been validated and has adequate reliabil-
ity. There are 28 items concerning ways of coping, and
each is rated on a four point scales (anchor points ranging
from not doing the coping strategy to doing it a lot). There
are 14 coping methods found in these 28 items; the scales
are as follows: Self-distraction, Active coping, Denial, Sub-
stance use, Use of emotional support, Use of instrumental
support, Behavioral disengagement, Venting, Positive
reframing, Planning, Humor, Acceptance, Religion, and
Self-blame. There are two items for each of these 14 cop-
ing methods; the sum of the two items is the score for that
particular coping method. Adequate psychometric prop-
erties of this instrument have been found [43].
Brief Pain Inventory
The Brief Pain Inventory [45] was administered to meas-
ure the severity of pain and the interference of pain in the
patient's life. Higher scores indicate more severe levels of
persistent pain and higher levels of interference with func-
tioning. This measure exhibits adequate levels of reliabil-
ity to assess pain in noncancer samples, with coefficient
alphas of .70 and above, also evidences good concurrent
validity with other generic pain measures, and has been
shown to be sensitive to changes in pain status over time
[46].
Pittsburg Sleep Quality Index
Sleep disturbances were examined by using the Pittsburg
Sleep Quality Index, which was developed to measure
sleep quality in psychiatric research [47]. This Index meas-
ures sleep disruptions and sleep quality. There are nine-
teen questions (on 0–3 scale) which generate seven
"component" scores: subjective sleep quality, sleep
latency, sleep duration, habitual sleep efficiency, sleep
disturbances, use of sleeping medication, and daytime
dysfunction. The sum of scores for these seven compo-
nents yields one global score, which can range from 0 to
21, with higher scores indicating worse sleep quality.
Actigraph
An actigraph is a small, light-weight, cost-efficient activity
monitor that can be worn on the waist. It has a long bat-
tery life and can continuously collect data every minute of
the day and night for 22 days before its memory is filled
to capacity [48]. Unlike most activity monitoring devices,
the actigraph is capable of recording movement intensity.
The actigraph transduces activity using an accelerometer.
An 8-bit analog-to-digital converter quantifies these meas-
urements into 128 levels of positive acceleration and 128
levels of negative acceleration 10 times each second. Inte-
gration over the resulting sampling time of 0.1 s in com-
bination with other details provided by Tryon and
Williams [48] would result in measurement units of 1.664
milli-g/activity activity count. For simplicity, analog-to-
digital (A/D) counts are retained as activity units. The
average of 600 absolute A/D values is stored in memory at
the end of every minute. Participants wore the actigraph
on their waist at all times except for when bathing or
sleeping for one week.
Six minute walking test
As an in vivo measure of physical functioning, the six
minute walking test [49] was used. The test measures the
distance walked during a six minute interval. The test is a
useful and reproducible measure of exercise tolerance,
provides a simple practical guide to everyday disability,
and does not require expensive apparatus [49].
Rating of Perceived Exertion
The Rating of Perceived Exertion (RPE) measures per-
ceived intensity of activity based on bodily sensations
such as increased heart rate and breathing [50]. Higher
scores indicate higher perceived exertion, with scores
ranging from 6 (no exertion) to 20 (maximal exertion).
The measure was given at 30 second intervals during the
six minute walk test. The RPE has evidenced good reliabil-
ity and validity, particularly for progressive exercise tests
[51].
Sit and reach
In order to gain an assessment of flexibility, we adminis-
tered the sit and reach test, which is the most widely-used
measure of flexibility and a primary component of most
physical fitness tests. The test is designed to measure the
extensibility of the hamstring muscles and the lower back
articulations by evaluating the maximal reach an individ-
ual can make in a seated position. This test has excellent
test-retest and intra-rater reliability [52].Page 4 of 9
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The hand dynamometer test was administered to measure
grip strength in pounds, and is a good measure of loss of
work capacity [53]. It is fast, easy to perform, and pro-
duces a reliable report that is simple to record [54].
Employment status
This measure of role function consisted of work status
(working vs. non-working). Employed included those
who were working at least 20 hours per week or in school
full-time. Unemployed included those who were retired,
working fewer than 20 hours per week, not in school, or
part-time student. We also assessed the number that are
receiving disability benefits, the number on disability or
temporary sick leave, and the number with work limita-
tions due to the illness.
Statistical analyses
Chi-square analyses were conducted between diagnostic
groups (i.e., CFS only; CFS-MCS; CFS-FM; CFS-MCS-FM)
and all categorical variables including race, gender, work
status, marital status, whether or not a participant had
children, and presence of psychiatric diagnoses. A series of
one-way ANOVAs were performed for continuous varia-
bles of age, socioeconomic status, fatigue severity, and dis-
ability. To decrease the likelihood of a Type 1 error, Tukey
HSD adjustments were made.
Results
Diagnostic status
Participants were categorized into four groups based on
their diagnostic status of CFS alone; CFS and MCS (CFS-
MCS); CFS and FM (CFS-FM); and CFS, MCS, and FM
(CFS-MCS-FM). Of the 114 participants, 50 (43.9%) met
criteria for CFS alone, 27 (23.7%) met criteria for CFS-
MCS, 18 (15.8%) met criteria for CFS-FM, and 19
(16.7%) met criteria for CFS-MCS-FM.
Sociodemographic characteristics
No significant differences were found across diagnostic
categories (CFS alone; CFS-MCS; CFS-FM; and CFS-MCS-
FM) for the sociodemographic variables of race, marital
status, gender, age, socioeconomic status, or whether or
not an individual had children. In regards to demographic
characteristics, 16.7 % of the participants were male and
83.3% were female. The average age at baseline was 43.8
years. Regarding ethnicity, 87.7 % were Caucasian, 4.4 %
were African-American, 4.4 % were Latino, and 3.5% were
Asian-American. As for marital status, 49.1 % were mar-
ried/living with someone, 33.3 % were single, and 17.6 %
were either divorced or separated. In terms of work status,
24.6 % were on disability, 23.7 % were unemployed, 20.2
% were working part-time, 19.3 % were working full-time,
6.1% were retired, 4.4 % were part-time students, .9%
were full-time students, and .9 % were working part-time
and on disability. In terms of education, 47.4% had
earned a standard college degree, 21.8% had a graduate or
professional degree, 21.1% had partial college, and 9.7%
had a high school/GED degree or less. Regarding psychi-
atric co-morbidity, 62.3% had a lifetime Axis 1 diagnosis,
and 38.6% had a current Axis 1 diagnosis.
Outcome measures
Whether individuals were working or not working was
examined across the four groups using χ2 analyses. There
were marginally significant differences across the four
groups, χ2 (3, N = 114) = 7.73, p=.052. The CFS alone
group had the highest percentage of working (54%),
while the CFS-MCS- FM group had the lowest percentage
of working (21.1%).
Outcome measures assessing fatigue severity, aspects of
disability, pain, sleep, depression, and coping among the
four diagnostic categories are presented in Table 1. An
ANOVA was used to compare the four diagnostic groups
on the eight scales of the MOS-SF-36. All post hoc tests
described below used Tukey HSD. Overall significant dif-
ferences were found for physical functioning (F (3, 108) =
4.40, p < .01), general health (F (3, 107) = 5.83, p < .001),
social functioning (F (3, 107) = 4.27, p < .01), and bodily
pain (F (3, 107) = 10.59, p < .001). Post hoc tests showed
that the CFS-MCS-FM group was significantly more disa-
bled than the CFS alone group on the physical function-
ing, general health, and bodily pain scales. Individuals
with CFS-MCS-FM were also more disabled than individ-
uals with CFS-MCS on the bodily pain scale. The former
group revealed more disability on the general health scale
than the CFS-FM group. There was a significant difference
on the bodily pain scale between the CFS alone group and
the CFS- FM group such that individuals with CFS- FM
were more disabled by pain than individuals with CFS
alone. Individuals with CFS-MCS were significantly more
disabled with regards to social functioning than individu-
als with CFS alone.
An ANOVA was conducted to compare individuals on the
Beck Depression Inventory. There was a significant differ-
ence in depression scores overall (F (3,107) = 3.20, p <
.05). Post hoc tests revealed that individuals with CFS-
MCS-FM experienced significantly more depression than
individuals with CFS alone (see Table 1). However, χ2
analyses did not yield significant differences in current
psychiatric diagnoses (χ2 (3, N = 114) = 2.71, p=.44) or
lifetime psychiatric diagnoses (χ2 (3, N = 114) = .85,
p=.84) across the four groups.
Findings from ANOVAs also showed significant overall
differences in sleep quality (F (3,106) = 4.08, P < .01), and
fatigue severity (F (3,107) = 3.20, p < .05). Post hoc anal-
yses revealed that individuals with CFS-MCS-FM experi-Page 5 of 9
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with CFS alone. Individuals with CFS-MCS were found to
have significantly higher fatigue severity than individuals
with CFS-FM (see Table 1).
The Brief Pain Inventory examined pain severity and pain
interference with functioning. ANOVAs revealed overall
significant differences between the four groups on pain
severity, F (3,104) = 11.65, p < .001. For this dimension,
Table 1: Outcome measures for individuals with CFS alone; CFS-MCS; CFS-FM; or CFS-MCS-FM
Outcome Measure CFS alone (n = 50) CFS-MCS (n = 27) CFS-FM (n = 18) CFS-MCS-FM (n = 19)
Mean (Standard Deviation)
MOS-SF-36
Physical Functioning 53.61 (25.05)a 42.50 (19.66) 40.56 (23.69) 32.89 (19.95)a
Role-Physical 4.69 (12.27) 3.85 (11.60) 4.17 (12.86) 3.95 (12.54)
Bodily Pain 49.83 (21.88)a,c 40.62 (21.63)b 30.00 (13.18)c 21.58 (18.60)a, b
General Health 36.65 (16.74)a 28.75 (15.94) 38.54 (16.62)b 19.95 (32.24)a, b
Vitality 20.73 (15.98) 15.19 (12.84) 19.72 (16.31) 11.32 (9.84)
Social Functioning 46.09 (25.15)a 30.29 (21.84)a 47.22 (23.70) 30.26 (19.68)
Role-Emotional 56.74 (45.00) 47.44 (45.39) 42.59 (35.80) 57.89 (41.34)
Mental Health 67.08 (16.30) 55.85 (19.35) 66.22 (14.79) 62.11 (18.10)
Brief COPE
Self Distraction 2.30 (0.87)a, b 2.91 (0.81)b 2.89 (0.88) 3.18 (0.65)a
Active Coping 2.97 (0.84) 3.15 (0.83) 3.28 (0.73) 3.10 (0.88)
Denial 1.41 (0.85) 1.28 (0.59) 1.25 (0.35) 1.32 (0.61)
Substance Use 1.15 (0.47) 1.22 (0.63) 1.53 (0.98) 1.24 (0.42)
Emotional Support 2.40 (0.95) 2.17 (0.91) 2.56 (0.97) 2.29 (0.85)
Instrumental Support 2.32 (0.96) 2.61 (0.93) 2.78 (0.75) 2.66 (0.99)
Behavioral 
Disengagement
1.33 (0.51) 1.27 (0.38) 1.47 (0.44) 1.47 (0.94)
Venting 1.93 (0.63) 2.09 (0.77) 2.39 (0.65) 2.11 (.077)
Positive Reframing 2.20 (1.06) 2.28 (0.94) 2.75 (0.96) 2.53 (1.05)
Planning 2.97 (0.97) 3.00 (0.98) 3.00 (0.86) 3.03 (0.86)
Humor 1.68 (0.79)a 1.78 (0.87) 2.39 (1.20)a 1.79 (0.77)
Acceptance 2.95 (0.88) 2.81 (0.83) 2.94 (0.75) 2.95 (0.80)
Religion 2.41 (1.01) 2.44 (0.97) 2.31 (1.06) 2.47 (1.05)
Self Blame 1.69 (0.87) 1.74 (0.75) 2.00 (0.77) 1.92 (0.79)
Beck Depression Inventory 16.47 (8.61)a 20.88 (9.64) 18.50 (9.54) 23.93 (11.43)a
Fatigue Severity Scale 5.98 (0.68) 6.35 (0.66)a 5.70 (1.22)a 6.30 (0.53)
Pittsburgh Sleep Quality 
Index
7.26 (2.53)a 8.69 (2.20) 8.94 (2.10) 8.95 (2.39)a
Brief Pain Inventory
Interference 2.83 (2.52)a, c,d 4.56 (2.78)b, c 5.36 (1.96)d 6.80 (2.33)a, b
Severity 3.03 (2.06)a, c 4.06 (2.02)b 4.86 (1.40)c 6.10 (2.04)a, b
Symptoms
Sore Throat 23.50 (26.61) 29.48 (26.97) 20.56 (26.40) 24.84 (28.82)
Tender Lymph Nodes 25.75 (30.36) 23.40 (26.33) 27.50 (33.79) 32.00 (27.92)
Muscle Pain 50.52 (28.34)a, b 60.76 (28.22) 72.92 (22.56)b 78.42 (24.97)a
Joint Pain 31.85 (33.25)a, c 46.04 (35.95)b 63.06 (32.18)c 75.50 (24.54)a, b
Impaired Memory 62.96 (25.22) 59.63 (23.82) 65.14 (25.53) 68.94 (22.65)
Unrefreshing Sleep 76.89 (18.89) 75.19 (25.43) 89.67 (10.86) 87.03 (14.46)
Post-Exertional Malaise 73.27 (17.84) 75.19 (19.16) 74.86 (23.74) 82.36 (14.10)
Headaches 42.91 (33.39)a 56.87 (30.50) 55.00 (31.44) 74.03 (24.39)a
Six Minute Walk Test
Distance Walked (feet) 1419.47 (312.17) 1728.08 (2387.62) 1304.28 (356.492) 1221.39 (239.23)
Average RPE 9.85 (2.24)a 10.56 (2.08) 11.37 (2.76) 11.78 (2.42)a
Sit and Reach (inches) 13.48 (3.54) 13.16 (4.49) 14.55 (4.24) 13.40 (3.77)
Hand Grip (pounds)
Right 64.45 (24.67) 61.57 (21.21) 64.19 (21.87) 52.28 (15.34)
Left 60.04 (22.71) 58.63 (17.90) 58.72 (20.71) 48.07 (17.21)
Actigraphy Mean 161.35 (58.55) 145.74 (58.13) 167.23 (48.51) 149.78 (63.12)
Lifetime Axis I Diagnosis % 21 (42.0%) 10 (37.0%) 6 (33.3%) 6 (31.6%)
Current Axis I Diagnosis % 17 (34.0%) 5 (18.5%) 7 (38.9%) 6 (31.6%)
Similar letters across diagnostic groups significantly differ at the p < .05 level.Page 6 of 9
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higher pain severity than individuals with CFS alone and
individuals with CFS-MCS. Additionally, individuals with
CFS-FM had significantly more pain severity than individ-
uals with CFS alone. The interference with functioning
dimension also revealed overall significant differences, F
(3, 103) = 12.44, p < .001. Post hoc analyses revealed that
individuals with CFS-MCS-FM had significantly more
interference in functioning due to pain than individuals
with CFS alone and individuals with CFS-MCS. Both indi-
viduals with CFS-MCS and individuals with CFS-FM had
significantly more interference in functioning due to pain
than individuals with CFS alone (see Table 1).
For the scales measuring coping, two revealed overall sig-
nificant differences, including self distraction (F (3,106) =
6.59, p < .001) and humor (F (3,107) = 2.90, p < .05).
Individuals with CFS-MCS, and individuals with CFS-
MCS-FM used significantly more self distraction than
individuals with CFS alone. Individuals with CFS-FM used
significantly more humor as a coping style than individu-
als with CFS alone (see Table 1).
ANOVAs were also conducted for severity of the eight core
CFS symptoms. There were significant group differences
for muscle pain (F (3,109) = 6.19, p < .001), joint pain (F
(3,110) = 9.96, p < .001), unrefreshing sleep (F (3,107) =
3.33, p < .05), and headaches (F (3,108) = 4.62, p < .01).
Table 1 shows the group differences based on post hoc
analyses. The CFS-MCS-FM group reported significantly
more severe muscle pain, joint pain, and headaches than
the CFS alone group. They also reported significantly
more joint pain severity than the CFS-MCS group. The
CFS-FM group reported significantly higher severity of
muscle pain and joint pain than the CFS alone group.
No significant differences were found across diagnostic
groups for physical measures including the six minute
walk test, sit and reach, hand grip strength, and actigra-
phy. Outcomes for physical measures are reported in
Table 1. During the six minute walk test, RPE was calcu-
lated every 30 seconds. Mean RPE scores were calculated,
and overall significant differences were found between
groups (F (3, 102) = 3.65, p < .05). Post hoc analyses
revealed that the CFS alone group had a significantly
lower RPE score than the CFS-MCS-FM group.
Discussion
These results suggest that a substantial number (56%) of
patients with CFS also meet criteria for MCS, FM, or both.
These findings are consistent with previous research indi-
cating high rates of overlap among these illnesses [11,23].
While some argue that distinguishing between these three
syndromes is not merited due to high rates of co-occur-
rence and overlapping symptom criteria [55], we found a
general pattern indicating that individuals with all three
diagnoses experience more overall difficulties when com-
pared to individuals with two or fewer diagnoses. Partici-
pants with CFS-MCS-FM experienced more depression
and poorer sleep quality than those with CFS alone. They
also had poorer physical functioning, more bodily pain,
and poorer general health than those with CFS alone.
Those with all three diagnoses also had lower general
health scores than those with CFS-FM, and more bodily
pain than those with CFS-MCS.
In addition, the CFS-MCS group had lower social func-
tioning scores on the SF-36 than those with CFS alone.
Our findings regarding the two groups that included indi-
viduals with MCS (CFS- MCS and CFS-MCS-FM) are con-
sistent with previous research suggesting that individuals
with MCS tend to have low scores on the SF-36 health sta-
tus scales [56]. Of note, the two MCS groups also utilized
self-distraction as a coping mechanism more than the CFS
alone, as measured by the Brief Cope. Self-distraction is
considered a maladaptive coping style on this measure
[57]. It has been hypothesized that individuals with MCS
may consider chemical exposure to be unavoidable, lead-
ing them to utilize passive coping [58]. Lower social func-
tioning of these individuals and a passive coping style
may be a consequence of not being able to avoid chemical
exposure.
Although pain is a symptom associated with CFS, it is the
hallmark symptom of FM. The two groups that included
individuals with FM (CFS-FM and CFS-MCS-FM) reported
more bodily pain on the SF-36 than the CFS alone and
CFS-MCS groups. Individuals with FM also reported more
pain severity and pain interference than the non-FM
groups. Additionally, among the eight core symptoms of
CFS, they reported more severe headaches, muscle pain,
and joint pain than the other groups. This suggests that
although many symptoms relating to pain overlap among
the disorders, pain-related symptoms are more salient
among patients with FM.
High rates of psychiatric comorbidity have been found in
studies of patients with CFS, MCS, and FM [59]. Our sam-
ple had rates of current psychiatric diagnosis ranging from
18.5% for the CFS-MCS group to 38.9% for the CFS-FM
group. In contrast to Ciccone and Natelson [23], we did
not find significant differences between groups with
regards to psychiatric illness. However, the CFS-MCS-FM
group had the highest depression scores, suggesting that
depression may be more prevalent in individuals who are
living with more severe disability.
We did not find differences between groups for the in vivo
physical measures of strength, exercise tolerance, and flex-
ibility. This is in contrast to the various differences foundPage 7 of 9
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and disability. Of note, the CFS-MCS-FM group rated a
significantly higher level of exertion on the six minute
walk test than the CFS alone group. It is possible that the
six minute walk test was not strenuous enough to detect
differences in performance across groups, but RPE scores
suggest that the task was more difficult for the CFS-MCS-
FM group. Future research might examine these differ-
ences during a higher-intensity activity.
Conclusion
It is important to note that all participants in this study
met diagnostic criteria for CFS; so many symptoms were
expected to be present across all participants. Individuals
with CFS alone were the highest functioning group across
several domains, such as disability, depression, and sever-
ity of symptoms. In contrast, participants with CFS-MCS-
FM experienced the greatest amount of overall disability.
However, physical measures of disability were not consist-
ent with these findings, as there were no differences across
groups. Individuals with all three diagnoses found the six
minute walk test to be more intense, as measured by RPE,
compared to the CFS alone group. This study provides evi-
dence that having more than one diagnosis exacerbates
one's disability above and beyond CFS alone.
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